The goal of this webinar series is to enhance understanding within the NCI and the research community of opportunities for targeting fusion oncoproteins through emerging chemoproteomic methods.
Proof-of-concept for the utility of blocking the action of transcription factor fusion oncoproteins has been achieved through menin inhibitors for KMT2A-rearranged leukemias, and agents targeting the menin-MLL protein-protein interaction are moving forward in clinical testing. However, progress in targeting additional transcriptional factor fusion oncoproteins remains limited. The expansion of chemoproteomic tools and capabilities creates opportunities for progress in directly targeting fusion oncoproteins and/or their critical dependencies, a point that was highlighted by the External Scientific Advisory Committee for the Cancer Moonshot-funded Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium in its recommendations to the NCI.
Registration is now open. This workshop is open to the public and free to attend. Recordings of individual sessions will be posted after completion of the session.
If you have further questions, please contact firstname.lastname@example.org or email@example.com